Moreover, by considering only neuroblastoma patients who showed relapse or progression of the disease and no MYCN amplification, lower expression of miR-181c was significantly associated with a worse prognosis (χ2 = 8.29, df = 1, p-value = 4.0e-03, n = 120) (Figure 4C). This evidence concerns the gene MYCN and neuroblastoma.